We evaluated the efficacy, safety, and tolerance of cefotaxime in 35 adults (25 with pleuropulmonary infections, 7 with genitourinary tract infections, and 3 with soft tissue infections). Of these 35 patients, 18 (51.4%) were seriously or critically ill. In vitro susceptibility testing revealed that 90.4% of the pathogens isolated were susceptible to cefotaxime (minimal inhibitory concentration, <8 ,ug/ml), 4.8% were intermediately susceptible (minimal inhibitory concentration, 8 to 32 ,ug/ml), and 4.8% were resistant (minimal inhibitory concentration, >32 ,ug/ml). A total of 34 of the 35 patients (97%) were clinically and bacteriologically cured of their infections. Adverse reactions occurred in two patients, but these reactions did not require interruption of therapy.
Cefotaxime is a new broad-spectrum derivative of 7-aminocephalosporanic acid which has marked in vitro activity and a high level of resistance to hydrolysis by P-lactamases (3-5, 7-9, 11) . In this study we evaluated the efficacy, safety, and toxicity of cefotaxime as single-drug therapy of serious bacterial infections in hospitalized adults.
MATERIALS AND METHODS
The patients included in this study were adults (12 to 90 years old) who were hospitalized in the Charleston Veterans Administration Medical Center, Charleston Memorial Hospital, or the Medical University of South Carolina Hospital. Any patient with an infection that required parenteral antibiotics was a potential candidate for the study and was referred to the investigators by the house staff for evaluation. Patients excluded from the study included (i) pregnant or lactating women, (ii) recipients within the previous 72 h of an antimicrobial agent to which the pathogen was susceptible, (iii) subjects hypersensitive to cephalosporins or wito type I hypersensitivity to penicillins, (iv) recipients of probenecid therapy during the preceding 2 weeks, and (v) individuals with serious hepatic disease or a rapidly fatal underlying illness. Patients were not excluded on the basis of the severity of their infectious process, and every effort was made to treat patients with life-threatening infections. All patients admitted to the study gave informed consent.
Before initiation of therapy, we obtained specimens for appropriate cultures, including two blood samples. In addition, we obtained a complete blood cell count and platelet count and performed direct and indirect Coombs' tests, urinalysis, and tests for blood urea nitrogen, creatinine, calcium, inorganic phosphorus, glucose, total protein, albumin, total bilirubin, aspartate, aminotransferase (glutamic-oxalacetic transaminase), alanine aminotransferase (glutamic-pyruvic transaminase), lactic dehydrogenase, and alkaline phosphatase. These laboratory tests were repeate'i on day 5 of therapy, every seventh day thereafter, and at the conclusion of therapy. Cultures of infected sites were repeated routinely on day 3 of therapy and after therapy was completed. In patients with genitourinary tract sepsis, follow-up cultures were also obtained 10
to 14 days after therapy ended.
Pretreatment specimens for bacteriological diagnosis were obtained personally by us, and these specimens were Gram stained and plated onto appropriate media within 20 to 30 min of collection. Sputum specimens from patients with lower respiratory tract infections were obtained by transtracheal aspiration or with a sterile Lukens trap immediately after intubation whenever possible. Expectorated sputum specimens were considered adequate if there was no more than one epithelial cell per low-power field and numerous polymorphonuclear leukocytes, with a marked predominance (>90%) of a single bacterial form as determined by oil immersion examination. Organisms were identified by using the API system (Analytab Products, Plainview, N.Y.) or the Dyntech MIC 2000 system (Dyntech Laboratories, Inc., Alexandria, Va.) or both. Minimal inhibitory concentrations (MICs) were determined by serial twofold dilutions in the appropriate broth, using an inoculum of 106 organisms per ml and an 18-h incubation. The minimal bactericidal concentrations (MBC) of a drug was considered that concentration which produced two or fewer colonies when 0.001 ml of broth was subcultured onto agar. Anaerobic MICs and MBCs were determined by the disk broth method (12) .
The 1-g and 500-mg ampoules of cefotaxime that were used for injection and for in vitro studies were supplied by Hoechst-Roussel Pharmaceutical Co., Somersville, N.J. For intravenous (i.v.) administration, 1 to 3 g of cefotaxime was dissolved in 10 to 30 ml of sterile water. These doses, diluted to 100-ml volumes in 5% glucose, were infused over a 10-to 15-min interval every 6 to 8 h. Whenever possible (in more than 90% of the cases), the site of i.v. administration was changed every 48 h. For intramuscular administration cefoiaxime was prepared by diluting 1 g of antibiotic in 2 ml of sterile water. Doses were injected into the lateral buttocks every 6 to 8 h. We saw all of the patients daily and evaluated the therapeutic efficacy by clinical, laboratory, and bacteriological criteria. Patients were considered clinically cured if all signs and symptoms of infection resolved, if laboratory indices returned to normal or base-line values, and if the radiographic studies showed definite improvement or resolution. Patients were considered bacteriologically cured if the causative organism(s) was eradicated from the infected site during and after completion of therapy. In one patient with a perirectal abscess and one patient with an empyema not associated with a pulmonary parenchymal infection, it was not possible to obtain posttreatment cultures, and clinical cure was taken to imply bacteriological cure.
Potential adverse effects of cefotaxime were detected by the previously mentioned laboratory tests and daily questioning and examination of each patient for adverse effects. However, in vitro susceptibility testing indicated that the E. cloacae and S. faecalis strains were resistant to cefotaxime. In view of the favorable clinical response shown by the patient, it was decided to repeat the in vitro testing, which again indicated that the E. cloacae and S. faecalis strains were resistant to cefotaxime. Therefore, according to the protocol, cefotaxime was discontinued after day 5 of therapy, and the patient was started on carbenicillin and tobramycin. At the time that cefotaxime was discontinued, cultures of the blood were negative, and cultures of the wound revealed eradication of S. faecalis and E. coli and a marked reduction in the amount of E. cloacae. Thus, although this patient had an excellent clinical response, he was considered a failure.
RESULTS
In vitro susceptibility testing revealed that 38 of the 42 pathogens isolated were susceptible to cefotaxime (MIC, <8 ,ug/ml), 2 isolates were intermediately susceptible (MIC, 8 to 32 ,ug/ml), and 2 isolates were resistant (MIC, >32 pLg/ml).
The susceptible Enterobacteriaceae isolates had a mean MIC of 0.049 ,ug/ml (range, 0.012 to 0.195 ,ug/ml). The one resistant Enterobacteriaceae isolate was an E. cloacae strain with an MIC of 100 FLg/ml. It should be noted that the initial disk susceptibility testing of this organism demonstrated a large zone of inhibition around the 30-,ug disk, with several minute colonies growing within the zone. This may have been analogous to the apparent enhanced in vitro activity of cefamandole against Enterobacter which can be demonstrated by agar susceptibility testing methods but not by broth susceptibility testing (1) . This discrepancy results from a high rate of mutation to cefamandole resistance, resulting in small-colony variants that are impossible or nearly impossible to detect by agar dilution methods (6) . The S. pneumoniae isolates had a mean MIC of 0.020 ,ug/ml (range, 0.0015 to 0.097 ,ug/ml), and the Haemophilus spp. isolates had a mean MIC of 0.014 ,ug/ml (range, 0.003 to 0.097 ,ug/ml). The two S. aureus isolates had MICs of 1.56 ,ug/ml. The three P. aeruginosa isolates had a mean MIC of 12.5 ,ug/ ml (range, 6.25 to 25.0 ,ug/ml). (10, 13) . P. aeruginosa appears to be intermediately susceptible or resistant to this antibiotic, and the eventual role of cefotaxime in therapy, alone or with another agent, against serious Pseudomonas infections remains to be defined.
In view of the greatly enhanced in vitro activity of cefotaxime, trials comparing high-dose therapy (4 to 12 g/day) with low-dose therapy (1 to 2 g/day) should be undertaken to determine the appropriate dosing regimen(s) for infections of the various organ systems. Our patients with S. pneumoniae and Haemophilus spp. pneumonia, as well as our patients with pyelonephritis, might have done equally well on a lower dosing regimen. Also deserving study is the potential role of cefotaxime in the therapy of meningitis. In our patient with meningitis caused by a highly resistant K. pneumoniae strain, cefotaxime proved to be life saving. In addition, there is at least one published report documenting the efficacy of cefotaxime in the treatment of meningitis in children infected with resistant organisms (2) .
